Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder

被引:49
作者
Revicki, Dennis A. [1 ]
Brandenburg, Nancy [2 ]
Matza, Louis [1 ]
Hornbrook, Mark C. [3 ]
Feeny, David [3 ,4 ]
机构
[1] United Biosource Corp, Ctr Hlth Outcomes Res, Bethesda, MD 20814 USA
[2] Pfizer Global Pharmaceut, New York, NY USA
[3] Kaiser Permanente NW, NW Hawaii SE, Ctr Hlth Res, Portland, OR USA
[4] Hlth Utilities Inc, Dundas, ON, Canada
关键词
Generalized anxiety disorder; Health-related quality of life; Anxiety symptoms; Health utility; Health utilities index; Primary-care patients;
D O I
10.1007/s11136-008-9406-6
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Generalized anxiety disorder (GAD) is prevalent and significantly impacts patient health-related quality of life (HRQL) and disability. This study evaluated the effect of GAD and anxiety symptom severity on the HRQL of primary-care patients with GAD. Patients 18 years or older with GAD were recruited from an integrated health care delivery system. Clinical assessments included the Hamilton Anxiety Rating Scale (HAM-A), GAD Questionnaire-IV (GAD-Q-IV), and the Patient Health Questionnaire depression module (PHQ). HRQL was assessed by the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF), Sheehan Disability Scale (SDS), SF-12 Health Survey (SF-6D), and the Health Utilities Index (HUI2, HUI3). The sample included 297 patients, 72% women with mean +/- standard deviation (SD) age of 47.6 +/- 13.7 years. At baseline, the mean HAM-A score was 16.8 +/- 7.6 (suggesting the presence of moderate anxiety symptoms). Anxiety and depression symptoms were significantly correlated with mental component summary (MCS), Q-LES-Q-SF, SDS, SF-6D, HUI2, and HUI3 scores (all P < 0.001). The mean HRQL and all of the preference-based measures varied significantly by anxiety severity groups (all P < 0.001). Anxiety and depression symptoms significantly predicted HRQL and preference-based scores (R-2 values ranged from 0.22 to 0.57). Anxiety symptoms reported by GAD patients resulted in significant impairment to HRQL and functional outcomes.
引用
收藏
页码:1285 / 1294
页数:10
相关论文
共 48 条
[1]
[Anonymous], QUALITY LIFE PHARMAC
[2]
[Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
[3]
Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study [J].
Ansseau, M ;
Fischler, B ;
Dierick, M ;
Mignon, A ;
Leyman, S .
EUROPEAN PSYCHIATRY, 2005, 20 (03) :229-235
[4]
High prevalence of mental disorders in primary care [J].
Ansseau, M ;
Dierick, M ;
Buntinkx, F ;
Cnockaert, P ;
De Smedt, J ;
Van Den Haute, M ;
Vander Mijnsbrugge, D .
JOURNAL OF AFFECTIVE DISORDERS, 2004, 78 (01) :49-55
[5]
The estimation of a preference-based measure of health from the SF-12 [J].
Brazier, JE ;
Roberts, J .
MEDICAL CARE, 2004, 42 (09) :851-859
[6]
EuroQol: The current state of play [J].
Brooks, R .
HEALTH POLICY, 1996, 37 (01) :53-72
[7]
Short-interval test-retest interrater reliability of the Structured Clinical Interview for DSM-III-R personality disorders (SCID-II) in outpatients [J].
Dreessen, L ;
Arntz, A .
JOURNAL OF PERSONALITY DISORDERS, 1998, 12 (02) :138-148
[8]
ENDICOTT J, 1993, PSYCHOPHARMACOL BULL, V29, P321
[9]
Multiattribute and single-attribute utility functions for the health utilities index mark 3 system [J].
Feeny, D ;
Furlong, W ;
Torrance, GW ;
Goldsmith, CH ;
Zhu, ZL ;
DePauw, S ;
Denton, M ;
Boyle, M .
MEDICAL CARE, 2002, 40 (02) :113-128
[10]
Feeny D., 1996, QUALITY LIFE PHARMAC, P239